February 2022 Top Biopharma Deal: Heidelberg – Huadong ATAC Candidates for Cancer Treatment
February 2022 Top Biopharma Deal Upfront
Heidelberg development and commercialization deal with Huadong for HDP-101, HDP-103, and options for two more ATAC candidates for cancer Asia ex-Japan
Announced: February 27, 2022
Total Deal Value: $1,048M
Upfront Cash: $20M
Upfront Equity: $118M
Option Payments: $461M
Milestones: up to $449M (dev., reg., and sales)
Royalty: Tiered single to low double-digits
Cost and Profit Split: n/a
Heidelberg’s ATAC project candidates HDP-101 and HDP-103 for cancer treatment with options for 2 additional candidates HDP-102 and HDP-104
Development and Commercial License
License hand-off for Asia ex-Japan; Options to add compounds
- Heidelberg granted Huadong exclusive rights to develop and commercialize HDP-101 and HDP-103 in Asia excluding Japan for the treatment of cancer. Additionally, Huadong will have an exclusive option for HDP-102 (CD37-ATAC) and HDP-104 in Asia.
- Heidelberg will receive $20M up front and is eligible for up to $449M in milestones for HDP-101 and HDP-103. Heidelberg is eligible for $461M if Huadong exercises its option. Heidelberg is eligible for tiered single to low double-digit royalties.
- Huadong will invest EUR 105M in Heidelberg representing 35% of shares, with an initial commitment of EUR 80M by purchasing 12,408,649 shares at EUR 6.44 per share.
- Heidelberg will approve the equity investment by July 2022 and will close the transaction on August 27 2022 and can expand the completion date until October 27, 2022 by issuing EUR 10M in the form of 12 months loan.
Congrats to Heidelberg and Huadong for landing DealForma’s February 2022 Top Biopharma Deal. Last month’s Deal of the Month was Beam – Pfizer In Vivo Base Editing and Delivery Programs for Rare Diseases. Read about it here.
DealForma’s Deal of the Month selection is based on the largest disclosed upfront cash and equity total in partnership deals involving R&D as announced in the month prior to this article. Data for this analysis was compiled using the DealForma biopharma deals database. All data are based on publicly disclosed figures and deal terms. We invite you to answer interesting questions on biopharma business development and licensing using our data and carefully curated profiles on deals, pipelines, companies, funding, and business executives by visiting dealforma.com to schedule your personalized demo.
Want data for your analysis? Want us to do it? Subscribers get both.
Schedule your demo of the DealForma database to see how we help you get better reports done faster.
Specifically for Biotech, Pharma, Device, and Diagnostics
Get more done.
Stop cleaning data or getting lost in legacy databases. We built DealForma to help you be better and faster at business research. Schedule your customized demo to see how DealForma helps you impress your boss and sign-off early.
More Research by DealForma
Biotech and pharma M&A total deal values slumped in 2020, despite an active year in life sciences dealmaking, with no big standout biopharma deals until late in the second half of the year. We look at the extensive DealForma database to see how life sciences M&A activity shaped up in 2020 in more detail.
This article is a sample from the DealForma Annual Deal Trends Report provided to database subscribers. Data for this analysis was compiled using the DealForma biopharma deals database. We applied initial filters for mergers and acquisitions, therapeutic areas, asset...
Over the last three years, there have been eight M&A deals for companies developing advanced first generation and next gen cancer cell therapies. Six of them have been completed to date.
We looked at 10 years of gene therapy deals, M&A, venture funding, and academic partnerships for an article by John Carroll at Endpoints News.
Biotech reverse mergers have been an alternate way for private biotechnology companies to gain a public listing. Here’s a quick table of over 10 years of deals.
2019 biopharma dealmaking started with a bang as the first quarter saw global biotech and pharma partnering deal values hit $38 billion in 282 deals.
Celgene was among the top investors in cancer biotech companies. This is a look at the top 10 since 2010.
Life Sciences M&A started with a bang in 2019 with one of the biggest deals to date – Bristol-Myers Squibb will acquire Celgene for $74 billion. We mined DealForma’s extensive database for historical M&A trends in biopharma, medical devices, and diagnostics to get an idea of what might lie ahead in 2019.
Innovative biotech companies are in a stronger position today as far as the value of their assets. We look at oncology deal payments by stage at signing.
Global biotechnology venture investment topped $11.8 billion in 258 financing rounds in the first 10 months of 2018. Who are the top biotech venture investors, where are they investing their money, and what are they investing in?
You met on Zoom. Now it's Deal Time.
With thousands of company profiles and a decade of deals specifically in biopharma and medtech, you'll take the guesswork out of deal comps. Schedule your customized demo to see how DealForma helps you win that term sheet with better data.